Researchers identify low MCJ expression as marker of poor response to chemotherapy
Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 (HER2).